<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611688</url>
  </required_header>
  <id_info>
    <org_study_id>NN8210-3926</org_study_id>
    <secondary_id>2011-003008-19</secondary_id>
    <secondary_id>U1111-1122-3474</secondary_id>
    <nct_id>NCT01611688</nct_id>
  </id_info>
  <brief_title>First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to describe the safety and
      tolerability of single intravenous (i.v.) and subcutaneous (s.c.) doses of NNC0215-0384 in
      subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2012</start_date>
  <completion_date type="Actual">June 17, 2013</completion_date>
  <primary_completion_date type="Actual">June 17, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 10 weeks after trial product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>I.v. administration: AUC, Area under the curve</measure>
    <time_frame>Up to 10 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>I.v. administration: terminal half-life (t½)</measure>
    <time_frame>Up to 10 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S.c. administration: AUC, Area under the curve</measure>
    <time_frame>Up to 10 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S.c. administration: terminal half-life (t½)</measure>
    <time_frame>Up to 10 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum level and duration of full C5a receptor (C5aR) occupancy by NNC0215-0384 on neutrophils</measure>
    <time_frame>Up to 10 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum levels of relevant serum and plasma biomarkers related to NNC0215-0384 safety, efficacy or mechanism of action (MoA)</measure>
    <time_frame>Up to 10 weeks after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Inflammation</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0215-0384</intervention_name>
    <description>I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0215-0384</intervention_name>
    <description>The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints
             and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at
             screening

          -  Concomitant treatment with MTX (7.5 - 25 mg/week both inclusive) for at least 16
             weeks, with a stable dose for at least 6 weeks prior to dosing

        Exclusion Criteria:

          -  Subjects with chronic inflammatory autoimmune disease other than RA

          -  History of or current inflammatory joint disease other than RA such as gout (crystal
             proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive
             arthritis or Lyme disease

          -  Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic
             pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to
             randomisation

          -  Clinically significant cardiac or cardiovascular disease

          -  Past or current malignancy

          -  Latent or active tuberculosis (TB) as documented by: A positive QuantiFeron® test
             (test can be performed up to 2 months prior to dosing). One retest is allowed in case
             of inconclusive results.- A history of active TB within the last 3 years even, if
             treated effectively. - A history of active TB more than 3 years ago, if there is no
             documentation that the prior anti-TB treatment was appropriate in duration and type
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

